FDA Approves Biosimilar Trastuzumab for HER+ Breast Cancer FDA Approves Biosimilar Trastuzumab for HER+ Breast Cancer

The agency has approved the first biosimilar that corresponds to Herceptin for use in HER2+ breast and metastatic stomach cancer.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news